

MINIREVIEW

Nomenclature for Macrolide and Macrolide-Lincosamide-Streptogramin B Resistance Determinants

MARILYN C. ROBERTS,^{1*} JOYCE SUTCLIFFE,² PATRICE COURVALIN,³
LARS BOGO JENSEN,⁴ JULIAN ROOD,⁵ AND HELENA SEPPALA⁶

Department of Pathobiology, University of Washington, Seattle, Washington 98195¹; Department of Infectious Diseases, Pfizer Central Research, Groton, Connecticut 06340-1596²; Unite des Agents Antibacterienes, Institut Pasteur, Paris Cedex 15, France³; Danish Veterinary Laboratory, DK-1790 Copenhagen, Denmark⁴; Department of Microbiology, Monash University, Clayton, Victoria 3168, Australia⁵; and Antimicrobial Research Laboratory, National Public Health Institute, FIN-20520 Turku, Finland⁶

Macrolides are composed of 14 (erythromycin and clarithromycin)-, 15 (azithromycin)-, or 16 (josamycin, spiramycin, and tylosin)-membered lactones to which are attached amino and/or neutral sugars via glycosidic bonds. Erythromycin was introduced in 1952 as the first macrolide antibiotic. Unfortunately, within a year, erythromycin-resistant (Em^r) staphylococci from the United States, Europe, and Japan were described (101). Erythromycin is produced by *Saccharopolyspora erythraea*, while the newer macrolides are semisynthetic molecules with substitutions on the lactone. The newer derivatives, such as clarithromycin and azithromycin, have improved intracellular and tissue penetration, are more stable, are better absorbed, have a lower incidence of gastrointestinal side effects, and are less likely to interact with other drugs. They are useable against a wider range of infectious bacteria, such as *Legionella*, *Chlamydia*, *Haemophilus*, and some *Mycobacterium* species (not *M. tuberculosis*), and their pharmacokinetics provide for less frequent dosing than erythromycin (21, 47, 96, 97). As a result, the usage of the newer macrolides has increased dramatically over the last few years, which has led to increased exposure of bacterial populations to macrolides (101–103, 107).

Macrolides inhibit protein synthesis by stimulating dissociation of the peptidyl-tRNA molecule from the ribosomes during elongation (101, 103). This results in chain termination and a reversible stoppage of protein synthesis. The first mechanism of macrolide resistance described was due to posttranscriptional modification of the 23S rRNA by the adenine-*N*⁶ methyltransferase (101–103). These enzymes add one or two methyl groups to a single adenine (A2058 in *Escherichia coli*) in the 23S rRNA moiety. Over the last 30 years, a number of adenine-*N*⁶-methyltransferases from different species, genera, and isolates have been described. In general, genes encoding these methylases have been designated *erm* (erythromycin ribosome methylation), although there are exceptions, especially in the antibiotic-producing organisms (see Tables 1 and 3) (103). As the number of *erm* genes described has grown, the nomenclature for these genes has varied and has been inconsistent (Table 1). In some cases, unrelated genes have been given the same letter designation, while in other cases, highly related genes (>90% identity) have been given different names.

The binding site in the 50S ribosomal subunit for erythromycin overlaps the binding site of the newer macrolides, as well as the structurally unrelated lincosamides and streptogramin B antibiotics. The modification by methylase(s) reduces the binding of all three classes of antibiotics, which results in resistance against macrolides, lincosamides, and streptogramin B antibiotics (MLS_B). The rRNA methylases are the best studied among macrolide resistance mechanisms (47, 101–103). However, a variety of other mechanisms have been described which also confer resistance (Table 2). Many of these alternative mechanisms of resistance confer resistance to only one or two of the antibiotic classes of the MLS_B complex.

In this review, we suggest a new nomenclature for naming MLS genes and propose to use the rules developed for identifying and naming new tetracycline resistance genes (51, 52). This system, with a few recent modifications, was originally designed because of the ability of two genes to be distinguished uniquely by DNA-DNA probe methodology (51). It was generally found that two genes with <80% amino acid sequence identity provided enough variability in nucleotide sequence to permit distinct probes to be designed. Although many investigators are likely to sequence new genes, the use of probe technology allows rapid identification of isolates containing potentially new genes, as well as a reliable way to screen populations and determine the frequency of any one resistant determinant. Therefore, we continued this paradigm by assigning two genes of ≥80% amino acid identity to the same class and same letter designation, while two genes that show ≤79% amino acid identity are given a different letter designation. Table 1 shows the results of the classification, with some classes having members with little variability, while others, like classes A and O, show a greater range of homology at both the DNA and amino acid levels. As new gene sequences emerge, ideally they will need to be compared by oligonucleotide probe hybridization and/or sequence analysis against the bank of known genes before a new designation is assigned. If multiple genes are available in any one class, especially when there is a range as in class A, then all representative members of the class should be examined, not just one. To confirm that the proposed name or number for the newly discovered resistance determinant has not been used by another investigator, please contact M. C. Roberts for this information. A similar request has been made for new *tet* genes (52).

* Corresponding author. Mailing address: Department of Pathobiology, Box 357238, University of Washington, Seattle, WA 98195. Phone: (206) 543-8001. Fax: (206) 543-3873. E-mail: marilynrc@u.washington.edu.

TABLE 1. rRNA methylase genes involved in MLS_B resistance

Class	Protein	Gene name	Gene(s) included	% Homology		Plasmid transposon ^c	GenBank no. or reference ^e
				DNA	Amino acid		
A	Erm(A)	<i>erm(A)</i>	<i>erm(A)</i> <i>erm(TR)</i>	83	81	Tn554	X03216 AF002716
B	Erm(B)	<i>erm(B)</i>	<i>erm(AM)</i> <i>erm(AM)</i> <i>erm(AM)</i> <i>erm(B)</i> <i>erm(B)</i> <i>erm(B)</i> <i>erm(AMR)</i> <i>erm(BC)</i> <i>erm(P)</i> , <i>erm(BP)</i> ^a <i>erm(IP)</i> <i>erm(Z)</i> , <i>erm(BZ1)</i> , <i>erm(BZ2)</i> ^a <i>erm</i> <i>erm(2)</i>	98–100	98–100	TnI545 pAMβ-1 pAM77 Tn917 pAD2 pIP501 pIP1527 pIP402 pIP501 Tn5398 pLEM3 pBT233, pMD101	X52632 Y00116 K00551 M36722 M11180 X72021 U86375 M19270 U18931 U00453 AF109075 U48430, X82819 X64695, X66468
C	Erm(C)	<i>erm(C)</i>	<i>erm(C)</i> <i>erm(C)</i> <i>erm(C)</i> <i>erm(C)</i> <i>erm(C)</i> <i>erm(C)</i> <i>erm(C)</i> <i>erm(C)</i> <i>erm(C)</i> <i>erm(C)</i> <i>erm(IM)</i> <i>erm(M)</i> <i>erm(M)</i> <i>erm(M)</i>	99–100	98–100	pE194 pT48 pE5 pJR5 pA22 pSES6 pSES5 pSES4a pSES21 J3356::pOX7 pIM13 pNE131 pPV141 pPV142	J01755, V01278 M19652 M17990 L04687 X54338 X82668 Y09001 Y09002 Y09003 U36911 M13761 M12730 U82607 AF019140
D ^d	Erm(D)	<i>erm(D)</i>	<i>erm(D)</i> <i>erm(J)</i> <i>erm(K)</i>	97–99	97–99	pBD90 pBA423	M29832 L08389 M77505
E	Erm(E)	<i>erm(E)</i>	<i>erm(E)</i> <i>erm(E2)</i>	99	96	pUC31, pIJ43	X51891 M11200
F	Erm(F)	<i>erm(F)</i>	<i>erm(F)</i> <i>erm(F)</i> <i>erm(FS)</i> <i>erm(FU)</i>	98–100	97–100	pBF4 Tn4351 pBI106, Tn4551 Chromosomal	M14730 M17124 M17808 M62487
G	Erm(G)	<i>erm(G)</i>	<i>erm(G)</i> <i>erm(G)</i>	99	99	pBD370 Tn7853	M15332 L42817
H ^b	Erm(H)	<i>erm(H)</i>	<i>car(B)</i>			pOJ159	P13079, M16503
I ^b	Erm(I)	<i>erm(I)</i>	<i>mdm(A)</i>				34
N ^b	Erm(N)	<i>erm(N)</i>	<i>tlr(D)</i>				X97721
O ^b	Erm(O)	<i>erm(O)</i>	<i>lrm</i> <i>srm(A)</i>	84	84	pLST391	M74717 AJ223970
Q	Erm(Q)	<i>erm(Q)</i>	<i>erm(Q)</i>			Chromosomal	L22689
R	Erm(R)	<i>erm(R)</i>	<i>erm(R)</i>				M11276
S ^b	Erm(S)	<i>erm(S)</i>	<i>erm(SF)</i> <i>tlr(A)</i>	100	100	pET23	M19269 P45439
T ^b	Erm(T)	<i>erm(T)</i>	<i>erm(GT)</i>			pGT633	M64090
U ^b	Erm(U)	<i>erm(U)</i>	<i>lmr(B)</i>			pPZ303	X62867
V ^b	Erm(V)	<i>erm(V)</i>	<i>erm(SV)</i>				U59450
W ^b	Erm(W)	<i>erm(W)</i>	<i>myr(B)</i>				M77505, P43433
X ^b	Erm(X)	<i>erm(X)</i>	<i>erm(CD)</i> , <i>erm(A)</i> ^b <i>erm(CX)</i>	99–100	99–100	pNG2 Tn5432	M36726, X51472 U21300
Y ^b	Erm(Y)	<i>erm(Y)</i>	<i>erm(GM)</i>			pMS97	57
Z ^b	Erm(2)	<i>erm(2)</i>	<i>srm(D)</i>				69
Unclassified			<i>clr</i>			pJI702	18

^a When two or three gene names are listed under “Genes included,” it means that the same gene was designated by two or three different names in the literature; for *erm(B)*, *erm(C)*, and *erm(M)*, multiple related genes have been sequenced, and a selection of these are listed, although they are not complete lists, since some of them have not been completely sequenced.

^b Newly designated classes, proteins, and genes given a single-letter designation rather than the two-letter or different three-letter designations currently used in the literature.

^c The list of plasmids includes both recombinant and natural plasmids.

^d Class D includes genes labeled in the literature as *erm(D)*, *erm(J)*, and *erm(K)*; because they share between 97 and 99% DNA and amino acid homology, they have been grouped under class D and *erm(D)*.

^e Information was provided by GenBank and references 10–12, 18, 25, 29, 31, 32, 34, 35, 37, 38, 42, 46, 55–57, 60–62, 65, 69, 71, 77, 88, 89, 91, 95, and 108–110.

TABLE 2. Efflux and inactivating genes

Resistance profile	Protein name	Gene included	Genes	% Homology		Plasmid ^b	GenBank no. or reference ^d
				DNA	Amino acid		
ATP-binding transporters							
Lincomycin	Car(A)	<i>car(A)</i>	<i>car(A)</i>	98	98	pOJ158	M80346
Erythromycin	Msr(A)	<i>msr(A)</i>	<i>msr(A)</i>			pUL5054 pSR1	X52085 AF167161
Streptogramin B			<i>msr(SA)</i> <i>msr(SA')</i> <i>msr(B)</i>			pEP2104 pMS97 pCH200	57 AB013298 M81802
Oleandomycin	Ole(B)	<i>ole(B)</i>	<i>ole(B)</i>			pALOR26E	L36601
Oleandomycin	Ole(C)	<i>ole(C)</i>	<i>ole(C)</i>				L06249
Spiramycin	Srm(B)	<i>srm(B)</i>	<i>srm(B)</i>			pKC514	X63451
Tylosin	Tlr(C)	<i>tlr(C)</i>	<i>tlr(C)</i>				M57437
Streptogramin A	Vga(A)	<i>vga(A)</i>	<i>vga</i>			pIP524 pIP1633	M90056
Streptogramin A	Vga(B)	<i>vga(B)</i>	<i>vga(B)</i>				U82085
Major facilitators							
Lincomycin	Lmr(A)	<i>lmr(A)</i>	<i>lmr(A)</i>			pLST21	X59926
Erythromycin	Mef(A)	<i>mef(A)</i>	<i>mef(A)</i>	90	91	p53-6 pAT15-5	U70055 U83667
Erythromycin			<i>mef(E)</i>				
Esterases							
Erythromycin	Ere(A)	<i>ere(A)</i>	<i>ere(A)</i>	99	99	pI1100, pAT63 pIP1527 pAT72	M11277 A15097 X03988
Erythromycin	Ere(B)	<i>ere(B)</i>	<i>ere(B)</i>				
Hydrolases							
Streptogramin B	Vgb(A)	<i>vgb(A)</i>	<i>vgb</i>			pIP524 pIP1714	M20129 AF015628
Streptogramin B	Vgb(B)	<i>vgb(B)</i>	<i>vgb(B)</i>				
Transferases							
Lincomycin	Lnu(A) ^a	<i>lnu(A)</i> ^c	<i>lin(A')</i>			pIP856 pIP855	J03947 M14039
Lincomycin			<i>lin(A)</i>				
Lincomycin	Lnu(B) ^a	<i>lnu(B)</i> ^c	<i>lin(B)</i>			pVMM25	AJ238249
Streptogramin A	Vat(A)	<i>vat(A)</i>	<i>vat</i>			pIP680 pIP524	L07778 L38809
Streptogramin A	Vat(B)	<i>vat(B)</i>	<i>vat(B)</i>				
Streptogramin A	Vat(C)	<i>vat(C)</i>	<i>vat(C)</i>			pIP1714 pAT15, pAT421	AF015628 L12033
Streptogramin A	Vat(D) ^a	<i>vat(D)</i>	<i>sat(A)</i>				
Streptogramin A	Vat(E) ^a	<i>vat(E)</i>	<i>sat(G)</i>				AF139725
Phosphorylases							
Macrolides	Mph(A)	<i>mph(A)</i>	<i>mph(A)</i>	99	93–99	pTZ3519 pGE64	D16251 U36578
Macrolides			<i>mph(K)</i>				
Macrolides	Mph(B)	<i>mph(B)</i>	<i>mph(B)</i>			pTZ3721, pTZ3723 pMS97	D85892 Q9ZNK8
Macrolides	Mph(C)	<i>mph(C)</i>	<i>mph(BM)</i>				
Macrolides			<i>mph(C)</i>	100	100	pSR1	AF167161

^a These are newly designated classes, proteins, and genes.

^b The list of plasmids includes both recombinant and natural plasmids.

^c New gene designation because the *lin* designation has been used for other genes. No genes use the *lnu* designation.

^d Information provide by GenBank and references 1–8, 14, 16, 17, 19, 23, 28, 30, 33, 34, 37–40, 42, 45, 47–50, 54, 55, 60, 63, 64, 66, 67, 69, 70, 72, 73, 83, 85, 87, 90, 93, 94, 99, 105, 110.

rRNA METHYLASES

Over the last 30 years, a large number of different rRNA methylase genes (*erm*) have been isolated from a variety of bacteria that range from *E. coli* to *Haemophilus influenzae* in gram-negative species and from *Streptococcus pneumoniae* to *Corynebacterium* spp. in gram-positive species (Table 3). In

addition, a variety of gram-positive and gram-negative anaerobes, and even spirochetes such as *Borrelia burgdorferi* and *Treponema denticola*, have all been shown to carry *erm* genes (Table 3) (36, 77, 78). All *erm* enzymes methylate the same adenine residue, resulting in an MLS_B phenotype (9, 100–103). This adenine (A2058) or one of the adjacent residues in the

TABLE 3. Location of antibiotic resistance genes^a

Gene	Genus or genera
Methylases	
<i>erm</i> (A)	<i>Actinobacillus</i> , <i>Staphylococcus</i> , <i>Streptococcus</i>
<i>erm</i> (B)	<i>Actinobacillus</i> , <i>Clostridium</i> , <i>Escherichia</i> , <i>Enterococcus</i> , <i>Klebsiella</i> , <i>Neisseria</i> , <i>Pediococcus</i> , <i>Staphylococcus</i> , <i>Streptococcus</i> , <i>Wolinella</i>
<i>erm</i> (C)	<i>Actinobacillus</i> , <i>Bacillus</i> , <i>Eubacterium</i> , <i>Lactobacillus</i> , <i>Neisseria</i> , <i>Staphylococcus</i> , <i>Streptococcus</i> , <i>Wolinella</i>
<i>erm</i> (D)	<i>Bacillus</i>
<i>erm</i> (E)	<i>Streptomyces</i>
<i>erm</i> (F)	<i>Actinobacillus</i> , <i>Actinomyces</i> , <i>Bacteroides</i> , <i>Clostridium</i> , <i>Eubacterium</i> , <i>Fusobacterium</i> , <i>Gardnerella</i> , <i>Haemophilus</i> , <i>Neisseria</i> , <i>Porphyromonas</i> , <i>Prevotella</i> , <i>Peptostreptococcus</i> , <i>Selenomonas</i> , <i>Streptococcus</i> , <i>Treponema</i> , <i>Veillonella</i> , <i>Wolinella</i>
<i>erm</i> (G)	<i>Bacillus</i> , <i>Bacteroides</i>
<i>erm</i> (H)	<i>Streptomyces</i>
<i>erm</i> (I)	<i>Streptomyces</i>
<i>erm</i> (N)	<i>Streptomyces</i>
<i>erm</i> (O)	<i>Streptomyces</i>
<i>erm</i> (Q)	<i>Actinobacillus</i> , <i>Clostridium</i> , <i>Streptococcus</i> , <i>Wolinella</i>
<i>erm</i> (R)	<i>Aeromicrobium</i>
<i>erm</i> (S)	<i>Streptomyces</i>
<i>erm</i> (T)	<i>Lactobacillus</i>
<i>erm</i> (U)	<i>Streptomyces</i>
<i>erm</i> (V)	<i>Streptomyces</i>
<i>erm</i> (W)	<i>Micromonospora</i>
<i>erm</i> (X)	<i>Corynebacterium</i>
<i>erm</i> (Y)	<i>Staphylococcus</i>
<i>clr</i>	<i>Streptomyces</i>
ATP-binding transporters	
<i>car</i> (A)	<i>Streptomyces</i>
<i>msr</i> (A)	<i>Staphylococcus</i>
<i>ole</i> (B)	<i>Streptomyces</i>
<i>ole</i> (C)	<i>Streptomyces</i>
<i>srn</i> (B)	<i>Streptomyces</i>
<i>itr</i> (C)	<i>Streptomyces</i>
<i>vga</i> (A)	<i>Staphylococcus</i>
<i>vga</i> (B)	<i>Staphylococcus</i>
Major facilitators	
<i>lmr</i> (A)	<i>Streptomyces</i>
<i>mef</i> (A)	<i>Corynebacterium</i> , <i>Enterococcus</i> , <i>Micrococcus</i> , <i>Staphylococcus</i> , <i>Streptococcus</i>
Esterases	
<i>ere</i> (A)	<i>Enterobacter</i> , <i>Escherichia</i> , <i>Klebsiella</i> , <i>Citrobacter</i>
<i>ere</i> (B)	<i>Escherichia</i> , <i>Klebsiella</i> , <i>Proteus</i>
Hydrolases	
<i>vgb</i> (A)	<i>Enterococcus</i> , <i>Staphylococcus</i>
<i>vgb</i> (B)	<i>Staphylococcus</i>
Transferases	
<i>lnu</i> (A)	<i>Staphylococcus</i>
<i>lnu</i> (B)	<i>Enterococcus</i>
<i>vat</i> (A)	<i>Staphylococcus</i>
<i>vat</i> (B)	<i>Staphylococcus</i>
<i>vat</i> (C)	<i>Staphylococcus</i>
<i>vat</i> (D)	<i>Enterococcus</i>
<i>vat</i> (E)	<i>Enterococcus</i>
Phosphorylases	
<i>mph</i> (A)	<i>Escherichia</i>
<i>mph</i> (B)	<i>Escherichia</i>
<i>mph</i> (C)	<i>Staphylococcus</i>

^a Data were taken from references 1, 2, 6, 8, 9, 14, 16, 19, 22, 27, 33, 34, 37–41, 43, 44, 47, 48, 53–57, 59–67, 69–85, 88, 90, 93, 94, 98, 100, 105, and 108–110.

peptidyltransferase region (A2057 or A2059) is changed to another nucleotide by mutation in macrolide-resistant *Mycobacterium intracellulare*, *Mycobacterium avium*, *Propionibacterium* spp., and *Helicobacter pylori* (58, 84, 100–103).

Differences between the various *erm* genes are seen in the

regulation of expression of the phenotype. Some of the enzymes are inducibly regulated by translational attenuation of a mRNA leader sequence; in the absence of erythromycin, the mRNA is in an inactive conformation due to a sequestered Shine-Dalgarno sequence, preventing efficient initiation of translation of the *erm* transcripts. Mutational analyses of the *erm*(C) leader peptide suggested that the peptide, (FS)IFVI, is critical for induction (103). However, when the *erm* peptides from the *erm* genes are compared, little sequence similarity is apparent (103). Recently, a second mechanism of regulation has been described in which the lack of erythromycin prevents the complete synthesis of the mRNA due to rho factor-independent termination. This type of regulation has been described for the *erm*(K) system (20), and by homology, we hypothesize that it may also exist for *erm*(D), as well as *erm*(J), because they are highly related and have been grouped together under class D (Table 1). In either system, inducible isolates, when tested, may appear to be susceptible or intermediately resistant to macrolides and susceptible to lincosamides. Erythromycin is generally a good inducer in most species; in animal or human streptococcal isolates, lincosamides and/or streptogramin B may be good inducers (47, 76). Good overviews of regulation of the *erm* genes can be found in recent reviews by Weisblum (100–103).

Inducible strains predominated in the 1960s to 1970s. However, today it is more common in many geographical areas to find isolates that constitutively produce the rRNA methylase without preexposure to antibiotics. Constitutive *erm* gene expression is usually associated with structural alterations in the *erm* translational attenuator, including deletions, duplications, and point mutations in *erm*(C) (104). They can be distinguished from inducible isolates by the stable MICs for them regardless of whether they are pregrown with or without an inducer (76, 102).

Many of the *erm* genes are associated with conjugative or nonconjugative transposons which tend to reside on the chromosomes, although some have been found in plasmids. They are often associated with other antibiotic resistance genes, especially tetracycline resistance genes. The *erm*(F) gene is often linked with the *tet*(Q) gene, while the *erm*(B) gene is often linked with the *tet*(M) gene (24, 86, 95). These conjugative transposons can have a wide host range, which may explain why clinical isolates of many different bacterial species have been found to carry these *erm* genes (Table 3). The *erm* genes in general have low G+C contents (31 to 34%), while the overall chromosomal G+C contents found in gram-negative species are $\geq 50\%$ and $\sim 35\%$ in gram-positive species.

It has been common practice for investigators to give their *erm* gene a new name regardless of the DNA and predicted amino acid sequence similarity to previously characterized *erm* genes and without regard to whether the gene resides in a different isolate, species, or genus. The result has been that, over the years, the names of these *erm* genes have become confusing, and often a complex table is required to remember which genes are closely related (Table 1). In the worst cases, genes for unrelated enzymes have been given the same name (*erm*(A)), causing confusion in the literature and GenBank listings (Table 1). The opposite also has occurred where very closely related or virtually identical enzymes have been given a variety of different names. For example, *erm*(F) (GenBank no. M14730) is found on the *Bacteroides* transposons Tn4351 and Tn4000 (71), *erm*(FS) (no. M17808) is on *Bacteroides* transposon Tn4551 (91), and *erm*(FU) (no. M62487) (32) is also from *Bacteroides*. All three enzymes share $\geq 97\%$ DNA and amino acid identity (Table 1). Since there are no phenotypic differences between the three *erm*(F) genes and distinguishing them

by any method other than sequencing is problematic, we propose that all three should be known as class F: the Erm(F) protein and the *erm*(F) gene (Table 1).

The situation is even worse with class B, which is composed of a larger number of genes, including *erm*(AM), *erm*(B), *erm*(BC), *erm*(BP), and *erm*(Z), whose sequences share $\geq 98\%$ homology (Table 1). Because the normal gene designation is to use a single letter (26) and the possibility of confusion between *erm*(A) and *erm*(AM), we propose that this group be known as class B: the *erm*(B) genes and the Erm(B) protein (Table 1). Recent dendrograms of many of the *erm* genes can be found in articles by Seppälä et al. (88) and Matsuoka et al. (56) and support this grouping of all of these genes within the class B designation.

To help those in the field, GenBank numbers or references for sequences that have not been deposited are listed in Table 1. If a new gene sequence shows $\geq 80\%$ amino acid homology to any member of a gene class and confers a similar phenotype to the host, we propose that the new gene be placed in the existing group and not be given a new letter or number designation. Thus, with classes that show a wide range of homologies, like class A (81% amino acid homology) or class O (84% amino acid homology), multiple members must be compared to the new gene. Note that the class designation is based on the amino acid sequence of the structural gene only and does not include the various regulatory sequences that can occur upstream of the gene. These guidelines are intended to apply to all of the *N*-methyltransferases, regardless of whether the gene was originally identified in pathogenic, opportunistic, normal flora bacteria or an antibiotic-producing species. Once all of the single capital letters have been used to identify new *erm* genes, we recommend naming genes as follows: *erm*(30), *erm*(31), etc. This system has been proposed for naming of new *tet* genes [*tet*(30), etc.] (52). Furthermore, a similar set of guidelines should be adopted for the genes that encode other mechanisms of resistance to any of the MLS antibiotics (Table 1). Class Y for gene *erm*(GM), class S for gene *erm*(SF), class T for gene *erm*(GT), class V for gene *erm*(SV), class X for genes *erm*(CD), *erm*(CX), and *erm*(A), and class 2 for gene *srn*(D) are new class designations that conform to the single-letter designation (Table 1).

There are a number of other methylase genes, most often found in methylase-producing organisms which have not been given *erm* designations, such as *thr*(D), *car*(B), *myr*(B), and *smr*(A). All are from species which confer resistance to a 16-membered ring macrolide (Table 1). We have grouped and renamed them classes H for *car*(B), I for *mdm*(A), N for *thr*(D), O for genes *lrm* and *srn*(A), U for *lmr*(B), and W for *myr*(B). The *clr* gene could not be classified, because there is no sequence in the database or literature available. Less work has been done to determine if these genes are found outside their respective antibiotic producers (Table 3). *erm* genes are often linked with *tet* genes, and since genes conferring resistance to oxytetracycline, originally found in antibiotic-producing streptomycetes, are now found in some clinical *Mycobacterium* isolates, it is certainly possible that some *erm* genes have also moved into *Mycobacterium* spp. and other genera (68).

To prevent two unrelated genes from being given the same designation, we propose to establish a reference center, as has recently been recommended for tetracycline resistance genes. By using the guideline presented above in governing the identification of new *erm* genes, surveys can be conducted in bacterial populations to examine the spread of particular MLS_B-resistant determinants. A single internal DNA fragment or oligonucleotide probe or a PCR assay that detects all members of a gene class can be established to screen large numbers of

isolates. Not only will the adoption of a uniform naming system reduce the number of new *erm* gene names, but it will hopefully prevent confusion over unrelated genes being given the same designation and also prevent highly related genes from having different gene designations.

EFFLUX SYSTEMS

A number of different antibiotic resistance genes code for transport (efflux) proteins. These do not modify either the antibiotic or the antibiotic target, but instead pump the antibiotic out of the cell or the cellular membrane, keeping intracellular concentrations low and ribosomes free from antibiotic. Many of these proteins [*mef*(A), *mef*(E), and *lmr*(A)] have homology to the major facilitator superfamily (MFS) of efflux proteins. Others [*car*(A), *msr*(A), *msr*(B), *ole*(B), *ole*(C), *srn*(B), *thr*(C), *vga*, and *vga*(B)] are putative members of the ABC transporter superfamily (70). In early years, most macrolide resistance was mediated by the presence of *erm* genes. However, more recently, other mechanisms of macrolide resistance have been found in increasing frequency in certain gram-positive populations (23, 27, 41, 43, 44, 92, 93, 106). Three different efflux systems which confer resistance have been described for gram-positive cocci [*msr*(A) (macrolide and streptogramin B resistant), *mef*(A) (macrolide efflux), and *vga* and *vga*(B) (virginiamycin factor A)] (4) (Table 2). Besides the academic interest in these genes, their presence in an erythromycin-resistant bacterial pathogen of interest may also have implications in terms of therapeutic choices. If an isolate carries a *mef* gene, clindamycin can be considered, whereas the presence of an *erm*(B) gene would preclude consideration of a lincosamide. Recently, we and others have identified *Streptococcus pneumoniae* strains which carry both *mef* and *erm*(B) genes and, as expected, have the MLS_B phenotype (41, 53).

The *mef* genes have been found in a variety of gram-positive genera, including corynebacteria, enterococci, micrococci, and a variety of streptococcal species (30, 43, 53, 90) (Table 3), suggesting a much wider distribution of this group of genes than originally imagined. Many of these genes are associated with conjugative elements located in the chromosome and are readily transferred conjugally across species and genus barriers (43, 53).

Two *mef* genes have been characterized in the literature: *mef*(A) (23) and *mef*(E) (94). The *mef*(A) gene was described in *Streptococcus pyogenes*, while the *mef*(E) gene was found in *S. pneumoniae*. Since the two genes share 90% DNA and 91% amino acid homology (Table 2), we recommended that these two genes be considered a single class, A: *mef*(A) gene and Mef(A) protein (Table 2).

The *msr*(A), *msr*(SA), *msr*(SA)', and *msr*(B) group differs from the *mef* genes because they confer resistance to both macrolide and streptogramin B antibiotics (MS) (13, 55–57). The *msr*(B) gene is roughly half the size of *msr*(A), but very homologous to it. Though this gene is significantly shorter than the *msr*(A) gene sequence, we placed it with the other *msr* genes (Table 2).

In antibiotic producers, there are efflux pumps specific for MLS_B antibiotics that generally belong to the ABC transporter superfamily (87). They include *car*(A) from *Streptomyces thermotolerans* (87), *ole*(B) from *Streptomyces antibioticus* (7, 80), *srn*(B) from *Streptomyces ambofaciens* (73), *lmr*(C) from *Streptomyces lincolnensis* (70), and *thr*(C) from *Streptomyces fradiae* (87). In addition to the *msr*(A) efflux pumps, there are two efflux systems identified in staphylococci that confer resistance to streptogramin A antibiotics, *vga* and *vga*(B) (4). Besides *mef*(A), other efflux proteins that appear to be fueled by the

proton motive force have been described for MLS_B antibiotics. A lincomycin-specific efflux pump encoded by *lmr*(A) has been described in *S. lincolnensis* (110).

OTHER MECHANISMS

A variety of other mechanisms which usually confer resistance to only one of the three classes (M, L, or S) or one component such as streptogramin A, but not streptogramin B, have been described (103) (Table 2). These proteins modify the antibiotic rather than the rRNA target or serve as pumps that shuttle the antibiotic out of the bacterial cell. Enzymes which hydrolyze streptogramin B [*vgb* (virginiamycin factor B hydrolase), *vgb*(B) genes] or modify the antibiotic by adding an acetyl group (acetyltransferases) to streptogramin A [*vat* (virginiamycin, factor A acetylation), *vat*(B), *vat*(C), *sat*(A), and *sat*(G) genes] have been described (1–6) (Table 2). Many of these genes are plasmid borne, and often these *vat*-related genes [*vat*, *vat*(B), and *vat*(C) genes] are downstream of other genes encoding resistance to streptogramins [*vgb*, *vga*(B), and *vgb*(B) genes, respectively] in staphylococci (2), but not in enterococci (72). The acetyltransferase genes are related, in the active site region, to a novel chloramphenicol acetyltransferase family of enzymes. We have renamed *sat*(A) as *vat*(D) and *sat*(G) as *vat*(E) to simplify the nomenclature (Table 2).

Unlike most of the other genes described in this review, both the *ere* (erythromycin esterification) and *mph* (macrolide phosphotransferase) genes (Table 2) were first described in *E. coli* rather than gram-positive cocci (8, 63, 64, 66, 67). According to our guidelines, *mph*(K) has been reassigned to *mph*(A), because there are only 10 amino acid (1%) differences between the two proteins. *mph*(BM) and *mph*(C) (66a) are grouped under Mph(C), because these genes are nearly identical to each other and distinct from *mph*(A) and *mph*(B) (Table 2). Several lincomycin nucleotidyltransferases have been identified: *lin*(A) in *Staphylococcus haemolyticus* (16), *lin*(A)' in *Staphylococcus aureus* (17), and *lin*(B) in *Enterococcus faecium* (14). We propose changing *lin*(A) and *lin*(B) to *lnu*(A) and *lnu*(B) (for lincomycin nucleotidyltransferase), because the former letters have already been used for gamma BHC dehydrochlorinase and cyclohexadiene hydrolase genes. It is suggested that prior to naming a new gene class, it is necessary to determine if the proposed three-letter designation has been used for other previously characterized genes.

CONCLUSIONS

With the introduction of the newer, more stable macrolides with enhanced properties, there has been a significant increase in macrolide usage. Macrolides like azithromycin and clarithromycin are recommended for prophylactic use to prevent *Mycobacterium avium* complex disease in human immunodeficiency virus patients. As macrolide use increases, so does its exposure to bacterial populations, increasing the opportunity for bacteria to acquire macrolide or MLS resistance. Given that intragenic transfer of macrolide-resistant determinants is possible (15), it is likely that all of the genes described in this review will spread into new species and that new genes will be identified. Therefore, it is important to clarify the nomenclature of these resistance genes for their expanding audience.

ACKNOWLEDGMENTS

We thank M. Matsuoka for providing unpublished material; B. Weisblum for discussions; J. Davies, C. J. Smith, and S. Schwarz for reading the manuscript; and S. Lerner for doing sequence comparisons.

REFERENCES

- Allignet, J., and N. El Solh. 1995. Diversity among the gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds and characterization of a new staphylococcal determinant, *vatB*. *Antimicrob. Agents Chemother.* **39**:2027–2036.
- Allignet, J., N. Liassine, and N. El Solh. 1998. Characterization of a staphylococcal plasmid related to pUB110 and carrying two novel genes, *vatC* and *vgbB*, encoding resistance to streptogramins A and B and similar antibiotics. *Antimicrob. Agents Chemother.* **42**:1794–1798.
- Allignet, J., V. Loncle, C. Simenel, M. Delepierre, and N. El Solh. 1993. Sequence of a staphylococcal gene, *vat*, encoding an acetyltransferase inactivating the A-type compounds of virginiamycin-like antibiotics. *Gene* **130**:91–98.
- Allignet, J., V. Loncle, and N. El Solh. 1992. Sequence of a staphylococcal plasmid gene, *vga*, encoding a putative ATP-binding protein involved in resistance to virginiamycin A-like antibiotics. *Gene* **117**:45–51.
- Allignet, J., V. Loncle, P. Mazodier, and N. El Solh. 1988. Nucleotide sequence of a staphylococcal plasmid gene, *vgb*, encoding a hydrolase inactivating the B components of virginiamycin-like antibiotics. *Plasmid* **20**:271–275.
- Allignet, J., and N. El Solh. 1995. Diversity among the gram-positive acetyltransferases inactivating streptogramin A and structurally related compounds and characterization of a new staphylococcal determinant, *vatB*. *Antimicrob. Agents Chemother.* **39**:2027–2036.
- Aparicio, G., A. Buche, C. Mendez, and J.-A. Salas. 1996. Characterization of the ATPase activity of the N-terminal nucleotide binding domain of an ABC transporter involved in oleandomycin secretion by *Streptomyces antibioticus*. *FEMS Microbiol. Lett.* **141**:157–162.
- Arthur, M., A. Andreumont, and P. Courvalin. 1987. Distribution of erythromycin esterase and rRNA methylase genes in members of the family *Enterobacteriaceae* highly resistant to erythromycin. *Antimicrob. Agents Chemother.* **31**:404–409.
- Arthur, M., A. Brisson-Noel, and P. Courvalin. 1987. Origin and evolution of genes specifying resistance to macrolides, lincosamides and streptogramin antibiotics: data and hypothesis. *J. Antimicrob. Chemother.* **20**:783–802.
- Berryman, D. I., and J. I. Rood. 1989. Cloning and hybridization analysis of *ermP*, a macrolide-lincosamide-streptogramin B resistance determinant from *Clostridium perfringens*. *Antimicrob. Agents Chemother.* **33**:1346–1353.
- Berryman, D. I., and J. I. Rood. 1995. The closely related *ermB-ermAM* genes from *Clostridium perfringens*, *Enterococcus faecalis* (pAMβ1), and *Streptococcus agalactiae* (pIP501) are flanked by variants of a directly repeated sequence. *Antimicrob. Agents Chemother.* **39**:1830–1834.
- Berryman, D. I., M. Lyrstis, and J. I. Rood. 1994. Cloning and sequence analysis of *ermQ*, the predominant macrolide-lincosamide-streptogramin B resistance gene in *Clostridium perfringens*. *Antimicrob. Agents Chemother.* **38**:1041–1046.
- Beyer, D., and K. Pepper. 1998. The streptogramin antibiotics: update on their mechanism of action. *Exp. Opin. Investig. Drugs* **7**:591–599.
- Bozdogan, B., L. Berrezouga, M.-S. Kuo, D. A. Yurek, K. A. Farley, B. J. Stockman, and R. LeClercq. 1999. A new resistance gene, *linB*, conferring resistance to lincosamides by nucleotidylation in *Enterococcus faecium* HM1025. *Antimicrob. Agents Chemother.* **43**:925–929.
- Brisson-Noël, A., M. Arthur, and P. Courvalin. 1988. Evidence for natural gene transfer from gram-positive cocci to *Escherichia coli*. *J. Bacteriol.* **170**:1739–1745.
- Brisson-Noel, A., and P. Courvalin. 1986. Nucleotide sequence of gene *linA* encoding resistance to lincosamides in *Staphylococcus haemolyticus*. *Gene* **43**:247–253.
- Brisson-Noel, A., P. Delrieu, D. Samain, and P. Courvalin. 1988. Inactivation of lincosaminide antibiotics in *Staphylococcus*. Identification of lincosaminide O-nucleotidyltransferases and comparison of the corresponding resistance genes. *J. Biol. Chem.* **263**:15880–15887.
- Calcutt, M. J., and E. Cundliffe. 1990. Cloning of a lincosamide resistance determinant from *Streptomyces caelestis*, the producer of celesticetin, and characterization of the resistance mechanism. *J. Bacteriol.* **172**:4710–4714.
- Cheng, J., T. Grebe, L. Wondrack, P. Courvalin, and J. Sutcliffe. 1999. Characterization of genes involved in erythromycin resistance in a clinical strain of *Staphylococcus aureus*, abstr. 837, p. 114. In Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
- Choi, S.-S., S.-K. Kim, T.-G. Oh, and E.-C. Choi. 1997. Role of mRNA termination in regulation of *ermK*. *J. Bacteriol.* **179**:2065–2067.
- Chu, D. 1995. Recent developments in 14- and 15-membered macrolides. *Exp. Opin. Investig. Drugs* **4**:65–94.
- Chung, W. O., C. Werckenthin, S. Schwarz, and M. C. Roberts. 1999. Host range of the *ermF* rRNA methylase gene in human and animal bacteria. *J. Antimicrob. Chemother.* **43**:5–14.
- Clancy, J., J. W. Petitpas, F. Dib-Hajj, W. Yuan, M. Cronan, A. Kamath, J. Bergeron, and J. Retsema. 1996. Molecular cloning and functional analysis

- of a novel macrolide-resistance determinant *mefA* from *Streptococcus pyogenes*. *Mol. Microbiol.* **22**:867–879.
24. Clewell, D. B., S. E. Flanagan, and D. D. Jaworski. 1995. Unconstrained bacterial promiscuity: the Tn916-Tn1545 family of conjugative transposons. *Trends Microbiol.* **3**:229–236.
 25. Cooper, A. J., N. B. Shoemaker, and A. A. Salyers. 1996. The erythromycin resistance gene from the *Bacteroides* conjugal transposon Tc^r Em^r 7853 is nearly identical to *ermG* from *Bacillus sphaericus*. *Antimicrob. Agents Chemother.* **40**:506–508.
 26. Council of Biology Editors, Inc. 1983. CBE style manual: a guide for authors, editors, and publishers in the biological sciences, 5th ed. Council of Biology, Editors, Inc., Bethesda, Md.
 27. Eady, E. A., J. I. Ross, J. L. Tipper, C. E. Walters, J. H. Cove, and W. C. Noble. 1993. Distribution of genes encoding erythromycin ribosomal methylases and an erythromycin efflux pump in epidemiologically distinct groups of staphylococci. *J. Antimicrob. Chemother.* **31**:211–217.
 28. Epp, J. K., S. G. Burgett, and G. E. Schoner. 1987. Cloning and nucleotide sequence of a carbomycin-resistance gene from *Streptomyces thermotolerans*. *Gene* **53**:73–83.
 29. Farrow, K. A., D. Lyras, and J. I. Rood. GenBank accession no. AF109075.
 30. Fraimow, H., and C. Knob. 1997. Amplification of macrolide efflux pumps *msr* and *mef* from *Enterococcus faecium* by polymerase chain reaction, abstr. A-125, p. 22. In Abstracts of the 98th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
 31. Hächler, H., F. H. Kayser, and B. Berger-Bächi. 1987. Homology of a transferable tetracycline resistance determinant of *Clostridium difficile* with *Streptococcus (Enterococcus) faecalis* transposon Tn916. *Antimicrob. Agents Chemother.* **31**:1033–1038.
 32. Halula, M., S. Manning, and F. L. Macrina. 1991. Nucleotide sequence of *ermFU*, macrolide-lincosamide-streptogramin (MLS) resistance gene encoding an RNA methylase from the conjugal element of *Bacteroides fragilis* V503. *Nucleic Acids Res.* **19**:3453.
 33. Hammerum, A. M., L. Jensen, L. Bogo, and F. M. Aarestrup. 1998. Detection of the *satA* gene and transferability of virginiamycin resistance in *Enterococcus faecium* from food-animals. *FEMS Microbiol. Lett.* **168**:145–151.
 34. Hara, Q., and C. R. Hutchinson. 1990. Cloning of midecamycin (MLS)-resistance genes from *Streptomyces mycarofaciens*, *Streptomyces lividans* and *Streptomyces coelicolor* A3(2). *J. Antibiot. (Tokyo)* **43**:977–991.
 35. Hodgson, A. L. M., J. Krywicki, and A. J. Radford. 1990. Nucleotide sequence of the erythromycin resistance gene from *Corynebacterium* plasmid pNG2. *Nucleic Acids Res.* **18**:1891.
 36. Hudson, C. R., M. C. Roberts, and F. C. Gherardini. 1998. Evidence of conjugal transfer of an erythromycin-resistance determinant in *Borrelia burgdorferi*, abstr. D-2, p. 223. In Abstracts of the 98th Annual Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
 37. Inouye, M., T. Morohoshi, S. Horinouchi, and T. Beppu. 1994. Cloning and sequences of two macrolides-resistance-encoding genes from mycinamicin-producing *Micromonospora griseorubida*. *Gene* **141**:39–46.
 38. Jenkins, G., M. Zalacain, and E. Cundliffe. 1989. Inducible ribosomal RNA methylation in *Streptomyces lividans*, conferring resistance to lincomycin. *J. Gen. Microbiol.* **129**:2703–2714.
 39. Jensen, L. B., A. M. Hammerum, F. M. Aarestrup, A. E. van den Bogaard, and E. E. Stobberingh. 1998. Occurrence of *satA* and *vgb* genes in streptogramin-resistant *Enterococcus faecium* isolates of animal and human origins in The Netherlands. *Antimicrob. Agents Chemother.* **42**:3330–3331.
 40. Jensen, L. B., N. Frimodt-Møller, and F. M. Aarestrup. 1999. Presence of *erm* gene classes in Gram-positive bacteria of animal and human origin in Denmark. *FEMS Microbiol. Lett.* **170**:151–158.
 41. Johnston, N. J., J. C. de Azavedo, J. D. Kellner, and D. E. Low. 1998. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of *Streptococcus pneumoniae*. *Antimicrob. Agents Chemother.* **42**:2425–2426.
 42. Kamimiya, S., and B. Weisblum. 1996. GenBank deposit: *Streptomyces viridochromogenes* rRNA (adenine-N6-) methyltransferase, *ermSV* gene. Accession no. U59450.
 43. Kataja, J., H. Seppälä, M. Skurnik, H. Sarkkinen, and P. Huovinen. 1998. Different erythromycin resistance mechanisms in group C and group G streptococci. *Antimicrob. Agents Chemother.* **42**:1493–1494.
 44. Kataja, J., P. Huovinen, M. Skurnik, the Finnish Study Group for Antimicrobial Resistance, and H. Seppälä. 1999. Erythromycin resistance genes in group A streptococci in Finland. *Antimicrob. Agents Chemother.* **43**:48–52.
 45. Kim, S.-K., M.-C. Baek, S.-S. Choi, B.-K. Kim, and E.-C. Choi. 1996. Nucleotide sequence, expression and transcriptional analysis of the *Escherichia coli* *mphK* gene encoding macrolide-phosphotransferase K. *Mol. Cells* **6**:153–160.
 46. Kovalic, D., R. B. Giannattasio, H.-J. Jin, and B. Weisblum. 1994. 23S rRNA domain V, a fragment that can be specifically methylated in vitro by the ErmSF (TrA) methyltransferase. *J. Bacteriol.* **176**:6992–6998.
 47. Leclercq, R., and P. Courvalin. 1991. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. *Antimicrob. Agents Chemother.* **35**:1267–1272.
 48. Leclercq, R., and P. Courvalin. 1991. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. *Antimicrob. Agents Chemother.* **35**:1273–1276.
 49. Le Goffic, F., M. L. Capmau, M. L. Bonnet, C. Cerceau, C. J. Soussy, A. Dublanquet, and J. Duval. 1977. Plasmid-mediated pristinamycin resistance: PHIA, a pristinamycin 1A hydrolase. *Ann. Inst. Pasteur* **128**:471–474.
 50. Le Goffic, F., M. L. Capmau, M. L. Bonnet, C. Cerceau, C. J. Soussy, A. Dublanquet, and J. Duval. 1977. Plasmid-mediated pristinamycin resistance: PCIIA, a new enzyme which modifies pristinamycin IIA. *J. Antibiot.* **30**:665–669.
 51. Levy, S. B., L. M. McMurry, V. Burdett, P. Courvalin, W. Hillen, M. C. Roberts, and D. E. Taylor. 1989. Nomenclature for tetracycline resistance determinants. *Antimicrob. Agents Chemother.* **33**:1373–1374.
 52. Levy, S. B., L. M. McMurry, T. M. Barbosa, V. Burdett, P. Courvalin, W. Hillen, M. C. Roberts, J. I. Rood, and D. E. Taylor. 1999. Nomenclature for new tetracycline resistance determinants. *Antimicrob. Agents Chemother.* **43**:1523–1524.
 53. Luna, V. A., P. Coates, E. A. Eady, J. Cove, T. T. H. Nguyen, and M. C. Roberts. 1999. A variety of Gram-positive bacteria carry mobile *mef* genes. *J. Antimicrob. Chemother.* **44**:19–25.
 54. Matsuoka, M., M. Inoue, and Y. Nakajima. 1995. A mechanism of resistance to partial macrolide and streptogramin B antibiotics in *Staphylococcus aureus* clinically isolated in Hungary. *Biol. Pharm. Bull.* **18**:1482–1486.
 55. Matsuoka, M., M. Inoue, and Y. Nakajima. 1997. A dyadic plasmid that shows MLS and PMS resistance in *Staphylococcus aureus*. *FEMS Microbiol. Lett.* **148**:91–96.
 56. Matsuoka, M., M. Inoue, and Y. Nakajima. 1998. A new class of *erm* genes mediating MLS-coresistance in *Staphylococcus aureus*: it resides on plasmid pMS97 together with *msrSA*^r gene coding for an active efflux pump, abstr. C-35, p. 78. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
 57. Matsuoka, M., K. Endou, H. Kobayashi, M. Inoue, and Y. Nakajima. 1998. A plasmid that encodes three genes for resistance to macrolide antibiotics in *Staphylococcus aureus*. *FEMS Microbiol. Lett.* **167**:221–227.
 58. Meier, A., P. Kirschner, B. Springer, V. A. Steingrube, B. A. Brown, R. J. Wallace, Jr., and E. C. Böttger. 1994. Identification of mutations in the 23S rRNA gene of clarithromycin-resistant *Mycobacterium intracellulare*. *Antimicrob. Agents Chemother.* **38**:381–384.
 59. Miller, E. S., C. R. Woese, and S. Brenner. 1991. Description of the erythromycin-producing bacterium *Arthrobacter* sp. strain NRRL B-3381 as *Aeromicrobium erythreum* gen. nov., sp. nov. *Int. J. Syst. Bacteriol.* **41**:363–368.
 60. Milton, I. D., C. L. Hewitt, and C. R. Harwood. 1992. Cloning and sequencing of a plasmid-mediated erythromycin resistance determinant from *Staphylococcus xylosum*. *FEMS Microbiol. Lett.* **76**:141–147.
 61. Monod, M., C. Denoya, and D. Dubnau. 1986. Sequence and properties of pIM13, a macrolide-lincosamide-streptogramin B resistance plasmid from *Bacillus subtilis*. *J. Bacteriol.* **167**:138–147.
 62. Monod, M., S. Mohan, and D. Dubnau. 1987. Cloning and analysis of *ermG*, a new macrolide-lincosamide-streptogramin B resistance element from *Bacillus sphaericus*. *J. Bacteriol.* **169**:340–350.
 63. Noguchi, N., A. Emura, H. Matsuyama, K. O'Hara, M. Sasatsu, and M. Kono. 1995. Nucleotide sequence and characterization of erythromycin resistance determinant that encodes macrolide 2'-phosphotransferase I in *Escherichia coli*. *Antimicrob. Agents Chemother.* **39**:2359–2363.
 64. Noguchi, N., J. Katayama, and K. O'Hara. 1996. Cloning and nucleotide sequence of the *mphB* gene for macrolide 2'-phosphotransferase II in *Escherichia coli*. *FEMS Microbiol. Lett.* **144**:197–202.
 65. Oh, T.-G., A.-R. Kwon, and E.-C. Choi. 1998. Induction of *ermAMR* from a clinical strain of *Enterococcus faecalis* by 16-membered-ring macrolide antibiotics. *J. Bacteriol.* **180**:5788–5791.
 66. O'Hara, K., T. Kanda, K. Ohmiya, T. Ebisu, and M. Kono. 1989. Purification and characterization of macrolide 2'-phosphotransferase from a strain of *Escherichia coli* that is highly resistant to erythromycin. *Antimicrob. Agents Chemother.* **33**:1354–1357.
 - 66a. O'Hara, K. Personal communication.
 67. Ounissi, H., and P. Courvalin. 1985. Nucleotide sequence of the gene *ereA* encoding the erythromycin esterase in *Escherichia coli*. *Gene* **35**:271–278.
 68. Pang, Y., B. A. Brown, V. A. Steingrube, R. J. Wallace, Jr., and M. C. Roberts. 1994. Tetracycline resistance determinants in *Mycobacterium* and *Streptomyces* species. *Antimicrob. Agents Chemother.* **38**:1408–1412.
 69. Pernodet, J. L., M. H. Blondelet-Rouault, and M. Guerineau. 1993. Resistance to spiramycin in *Streptomyces ambifaciens*, the producer organism, involves at least two different mechanisms. *J. Gen. Microbiol.* **139**:1003–1011.
 70. Peschke, U., H. Schmidt, H.-Z. Zhang, and W. Piepersberg. 1995. Molecular characterization of the lincomycin-production gene cluster of *Streptomyces lincolnensis* 78-11. *Mol. Microbiol.* **16**:1137–1156.

71. Rasmussen, J. L., D. A. Odelson, and F. L. Macrina. 1986. Complete nucleotide sequence and transcription of *ermF*, a macrolide-lincosamide-streptogramin B resistance determinant from *Bacteroides fragilis*. *J. Bacteriol.* **168**:523–533.
72. Rende-Fournier, R., R. LeClercq, M. Galimand, J. Duval, and P. Courvalin. 1993. Identification of the *satA* gene encoding a streptogramin A acetyltransferase in *Enterococcus faecium* BM4145. *Antimicrob. Agents Chemother.* **37**:2119–2125.
73. Richardson, M. A., S. Kuhstoss, P. Solenberg, N. A. Schaus, and R. N. Rao. 1987. A new shuttle cosmid vector, pKC505, for streptomycetes: its use in the cloning of three different spiramycin-resistance genes from a *Streptomyces ambovaciensis* library. *Gene* **61**:231–241.
74. Roberts, A. N., G. S. Hudson, and S. Brenner. 1985. An erythromycin-resistance gene from an erythromycin-producing strain of *Arthrobacter* sp. *Gene* **35**:259–270.
75. Roberts, M. C. 1995. Distribution of tetracycline and macrolides-lincosamides-streptogramin B (MLS) genes in anaerobic bacteria. *Clin. Infect. Dis.* **20**:S367–S369.
76. Roberts, M. C., and M. B. Brown. 1994. Macrolide-lincosamide resistance determinants in streptococcal species isolated from the bovine mammary gland. *Vet. Microbiol.* **40**:253–261.
77. Roberts, M. C., W. O. Chung, and D. E. Roe. 1996. Characterization of tetracycline and erythromycin determinants in *Treponema denticola*. *Antimicrob. Agents Chemother.* **40**:1690–1694.
78. Roberts, M. C., W. O. Chung, D. Roe, M. Xia, C. Marquez, G. Borthagaray, W. L. Whittington, and K. K. Holmes. 1999. Erythromycin-resistant *Neisseria gonorrhoeae* and oral commensal *Neisseria* spp. carry known rRNA methylase genes. *Antimicrob. Agents Chemother.* **43**:1367–1372.
79. Roberts, M. C., L. V. McFarland, P. Mullany, and M. E. Mulligan. 1994. Characterization of the genetic basis of antibiotic resistance in *Clostridium difficile*. *J. Antimicrob. Chemother.* **33**:419–429.
80. Rodriguez, A. M., C. Olano, C. Vilches, C. Mendez, and J. A. Salas. 1993. *Streptomyces antibioticus* contains at least three olendomycin resistance determinants, one of which shows homology with proteins of the ABC-transporter superfamily. *Mol. Microbiol.* **8**:571–582.
81. Roe, D. E., A. Weinberg, and M. C. Roberts. 1995. Mobility of rRNA methylase genes in *Campylobacter (Wolinella) rectus*. *J. Antimicrob. Chemother.* **36**:738–740.
82. Roe, D. E., A. Weinberg, and M. C. Roberts. 1996. Mobile rRNA methylase genes in *Actinobacillus actinomycetemcomitans*. *J. Antimicrob. Chemother.* **37**:457–464.
83. Ross, J. I., E. A. Eady, J. H. Cove, and S. Baumberg. 1996. Minimal functional system required for expression of erythromycin resistance by *msrA* in *Staphylococcus aureus* RN4220. *Gene* **183**:143–148.
84. Ross, J. I., E. A. Eady, J. H. Cove, C. E. Jones, A. H. Ratyal, Y. W. Miller, S. Vyakrnam, and W. J. Cunliffe. 1989. Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA. *Antimicrob. Agents Chemother.* **41**:1162–1165.
85. Rosteck, P. R., Jr., P. A. Reynolds, and C. L. Hershberger. 1991. Homology between proteins controlling *Streptomyces fradiae* tylosin resistance and ATP-binding transport. *Gene* **102**:27–32.
86. Salyers, A. A., N. B. Shoemaker, A. M. Stevens, and L.-Y. Li. 1995. Conjugative transposons: an unusual and diverse set of integrated gene transfer elements. *Microbiol. Rev.* **59**:579–590.
87. Schoner, B., M. Geistlich, P. I. Rosteck, Jr., R. N. Rao, E. Seno, P. Reynolds, K. Cox, S. Burgett, and C. Hershberger. 1992. Sequence similarity between macrolide-resistance determinants and ATP-binding transport proteins. *Gene* **115**:93–96.
88. Seppälä, H., M. Skurnik, H. Soini, M. C. Roberts, and P. Huovinen. 1998. A novel erythromycin resistance methylase gene (*ermTR*) in *Streptococcus pyogenes*. *Antimicrob. Agents Chemother.* **42**:257–262.
89. Shoemaker, N. B., R. D. Barber, and A. A. Salyers. 1989. Cloning and characterization of a *Bacteroides* conjugal tetracycline-erythromycin resistance element by using a shuttle cosmid vector. *J. Bacteriol.* **171**:1294–1302.
90. Shortridge, V. D., R. K. Flamm, N. Ramer, J. Beyer, and S. K. Tanaka. 1996. Novel mechanism of macrolide resistance in *Streptococcus pneumoniae*. *Diagn. Microbiol. Infect. Dis.* **26**:73–78.
91. Smith, C. J. 1987. Nucleotide sequence analysis of Tn4551: use of *ermFS* operon fusions to detect promoter activity in *Bacteroides fragilis*. *J. Bacteriol.* **169**:4589–4596.
92. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. *Antimicrob. Agents Chemother.* **40**:2562–2566.
93. Sutcliffe, J., A. Tait-Kamradt, and L. Wondrack. 1996. *Streptococcus pneumoniae* and *Streptococcus pyogenes* resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. *Antimicrob. Agents Chemother.* **40**:1817–1824.
94. Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. *meFE* is necessary for the erythromycin-resistant M phenotype in *Streptococcus pneumoniae*. *Antimicrob. Agents Chemother.* **41**:2251–2255.
95. Trieu-Cuot, P., C. Poyart-Salmeron, C. Carlier, and P. Courvalin. 1990. Nucleotide sequence of the erythromycin resistance gene of the conjugative transposon Tn1545. *Nucleic Acids Res.* **18**:3660.
96. Vergis, E. N., and V. L. Yu. 1997. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. *Semin. Respir. Infect.* **12**:322–328.
97. Vergis, E. N., and V. L. Yu. 1998. New macrolides or new quinolones as monotherapy for patients with community-acquired pneumonia; our cup runneth over? *Chest* **113**:1158–1159.
98. Wasteson, Y., D. E. Robe, K. Falk, and M. C. Roberts. 1996. Characterization of tetracycline and erythromycin resistance in *Actinobacillus pleuropneumoniae*. *Vet. Microbiol.* **48**:41–50.
99. Weber, J. M., J. O. Leung, G. T. Main, R. H. B. Potenz, T. J. Paulus, and J. P. DeWitt. 1990. Organization of a cluster of erythromycin genes in *Saccharopolyspora erythraea*. *J. Bacteriol.* **172**:2372–2383.
100. Weisblum, B. 1999. Resistance to macrolide-lincosamide-streptogramin antibiotics, p. 682–698. In V. A. Fischetti (ed.), *Gram-positive pathogens*. American Society for Microbiology, Washington, D.C.
101. Weisblum, B. 1995. Erythromycin resistance by ribosome modification. *Antimicrob. Agents Chemother.* **39**:577–585.
102. Weisblum, B. 1995. Insights into erythromycin action from studies of its activity as inducer of resistance. *Antimicrob. Agents Chemother.* **39**:797–805.
103. Weisblum, B. 1998. Macrolide resistance. *Drug Resist. Update* **1**:29–41.
104. Werckenthin, C., S. Schwarz, and H. Westh. 1999. Structural alterations in the translational attenuator of constitutively expressed *ermC* genes. *Antimicrob. Agents Chemother.* **43**:1681–1685.
105. Werner, G., and W. Witte. 1999. Characterization of a new enterococcal gene, *satG*, encoding a putative acetyltransferase conferring resistance to streptogramin A compounds. *Antimicrob. Agents Chemother.* **43**:1813–1814.
106. Widdowson, C. A., and K. P. Klugman. 1998. Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa. *Emerg. Infect. Dis.* **4**:277–281.
107. Young, H., A. Moyes, and A. McMillan. 1997. Azithromycin and erythromycin resistant *Neisseria gonorrhoeae* following treatment with azithromycin. *Int. J. Sex. Transm. Dis. AIDS* **8**:299–302.
108. Zalacain, M., and E. Cundliffe. 1989. Methylation of 23S rRNA caused by *thrA (ermSF)*, a tylosin resistance determinant from *Streptomyces fradiae*. *J. Bacteriol.* **171**:4254–4260.
109. Zalacain, M., and E. Cundliffe. 1991. Cloning of *thrD*, a fourth resistance gene, from the tylosin producer, *Streptomyces fradiae*. *Gene* **97**:137–142.
110. Zhang, H.-Z., H. Schmidt, and W. Piepersberg. 1992. Molecular cloning and characterization of two lincomycin-resistance genes, *lmrA* and *lmrB*, from *Streptomyces lincolnensis* 78-11. *Mol. Microbiol.* **6**:2147–2157.